Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Other Non-Current Liabilities (2020 - 2025)

Historic Other Non-Current Liabilities for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to $360000.0.

  • Arcutis Biotherapeutics' Other Non-Current Liabilities fell 1428.57% to $360000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $360000.0, marking a year-over-year decrease of 1428.57%. This contributed to the annual value of $570000.0 for FY2024, which is 3286.22% down from last year.
  • According to the latest figures from Q3 2025, Arcutis Biotherapeutics' Other Non-Current Liabilities is $360000.0, which was down 1428.57% from $360000.0 recorded in Q2 2025.
  • Arcutis Biotherapeutics' Other Non-Current Liabilities' 5-year high stood at $849000.0 during Q4 2023, with a 5-year trough of $12000.0 in Q2 2022.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $250000.0 (2024), whereas its average is $256357.1.
  • As far as peak fluctuations go, Arcutis Biotherapeutics' Other Non-Current Liabilities tumbled by 8397.44% in 2021, and later surged by 8556.7% in 2025.
  • Arcutis Biotherapeutics' Other Non-Current Liabilities (Quarter) stood at $25000.0 in 2021, then crashed by 52.0% to $12000.0 in 2022, then skyrocketed by 6975.0% to $849000.0 in 2023, then crashed by 32.86% to $570000.0 in 2024, then tumbled by 36.84% to $360000.0 in 2025.
  • Its last three reported values are $360000.0 in Q3 2025, $360000.0 for Q2 2025, and $360000.0 during Q1 2025.